This review summarizes the cellular and molecular mechanisms of adenosine's cardiovascular actions, highlighting advancements in receptor subtypes and physiological roles.
Summarizes adenosine receptor mechanisms in CV system; leaves open clinical translation pending prospective trials.
The remarkably comprehensive qualitative description of the cardiovascular actions of adenosine by Drury and Szent-Györgyi [(1929): J Physiol 6:213–237] serves as a framework for current research on the cellular and molecular mechanisms of those actions. This article reviews eight areas in this field that have advanced significantly during the past 5 years: (1) the kinds of potassium channels coupled to the cardiomyocyte A1AR; (2) the mechanism of the anti-adrenergic" action of adenosine; (3) the role of adenosine in angina pectoris; (4) the role of adenosine in ischemic preconditioning; (5) the occurrence of A2AR in ventricular myocytes; (6) evidence for A1-, A2A-, A2B- and A3ARs in blood vessels; (7) the role of nitric oxide in adenosine-initiated vasodilation; and (8) the effect of adenosine on microvascular permeability. In some areas, solid evidence has defined a particular mechanism; in others, the evidence is as yet incomplete. Drug Dev. Res. 39:301–307, 1996 © 1997 Wiley-Liss, Inc.
No takes yet. Share an insight, caveat, or question.
Ray A. Olsson (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: